Module 11: Complex Alterations: Gene Fusions, Amplifications & Immunotherapy Eligibility
Tested Stacks:
GATK 4.6.1
Samtools 1.21
Nextflow 24.10
Seurat v5.1
Python 3.12
Prerequisites: Basic Linux CLI & Sequencing Formats
📚 Chapter 11 of 12
0% Course Completed
1. Actionable Oncogenic Gene Fusions in Solid Tumors
Chromosomal rearrangements (translocations, inversions, interstitial deletions) can fuse the promoter and 5' exons of an actively transcribed partner gene to the 3' intact kinase domain of an oncogenic receptor tyrosine kinase. The resulting chimeric fusion protein escapes normal regulatory auto-inhibition, undergoes constitutive ligand-independent dimerization, and drives uncontrolled downstream oncogenic signaling.
| Fusion Oncogene | Common Partner Genes | Prevalence by Cancer Type | FDA-Approved Targeted Therapies |
|---|---|---|---|
| ALK | EML4 (inversion inv(2)(p21p23)), KIF5B, TFG | ~3% – 5% in NSCLC (younger, non-smokers) | Alectinib, Brigatinib, Lorlatinib (3rd gen, BBB-penetrant), Crizotinib |
| ROS1 | CD74, EZR, SDC4, SLC34A2 | ~1% – 2% in NSCLC, cholangiocarcinoma | Crizotinib, Entrectinib, Repotrectinib |
| NTRK1 / NTRK2 / NTRK3 | ETV6, LMNA, TPM3 | Pan-cancer (< 1% common tumors; > 90% rare tumors like secretory breast carcinoma) | Tissue-Agnostic Approval: Larotrectinib, Entrectinib |
| RET | KIF5B, CCDC6, NCOA4 | ~1% – 2% in NSCLC; > 50% in Medullary Thyroid Carcinoma | Selpercatinib, Pralsetinib |
2. Focal Oncogene Amplifications & Targeted Overexpression
Unlike whole-arm chromosomal aneuploidies, focal amplifications represent localized chromosomal amplifications ($> 6 - 10$ gene copies) that lead to massive protein overexpression:
- ERBB2 (HER2) Amplification: Observed in 15–20% of invasive breast carcinomas and 10–15% of gastroesophageal adenocarcinomas. Establishes eligibility for monoclonal antibody regimens (Trastuzumab, Pertuzumab) and antibody-drug conjugates (ADCs, such as Trastuzumab deruxtecan / T-DXd).
- MET Amplification: Represents a dominant mechanism of acquired secondary resistance (~15–20%) in patients with EGFR-mutant NSCLC progressing on first-line Osimertinib. Co-inhibition with MET TKIs (Tepotinib, Capmatinib, Amivantamab) overcomes this resistance.
3. Immunotherapy Biomarker Integration: TMB & MSI Synthesis
| Biomarker Status | Biological Mechanism | Clinical Actionability | Key Guideline Recommendation |
|---|---|---|---|
| MSI-High / dMMR | Loss of mismatch repair causes hypermutation across microsatellite repeats. | FDA Tissue-Agnostic: Pembrolizumab or Dostarlimab monotherapy; Nivolumab + Ipilimumab in CRC. | NCCN Category 1 recommendation for advanced MSI-H solid tumors. |
| TMB-High ($\ge 10 ext{ mut/Mb}$) & MSS | High somatic mutation count generating neoantigens, but intact MMR machinery. | FDA Approval: Pembrolizumab for refractory metastatic solid tumors. | High clinical response in NSCLC, melanoma, bladder cancer; lower response in colorectal/pancreatic MSS tumors. |
| TMB-Low ($< 10 ext{ mut/Mb}$) & MSS | Immunologically "cold" tumors; low neoantigen load. | Poor response to single-agent immune checkpoint blockade. | Direct patient toward targeted kinase inhibitors or cytotoxic chemotherapy combinations. |
⚠️
Common Pitfalls & Troubleshooting Checklist
- Java Heap Exhaustion (GATK / Picard): If processes terminate with
java.lang.OutOfMemoryError, set your environment variable explicitly:export _JAVA_OPTIONS="-Xmx16g -Djava.io.tmpdir=/tmp". - Index Timestamp Mismatch: If tools complain that a BAM index is missing or out of date, regenerate with
samtools index -@ 4 sample.bam. - Conda Channel Conflicts: Avoid ABI incompatibilities between bioconda and conda-forge by setting strict priority:
conda config --set channel_priority strict. - Chromosome Naming Contamination: Always verify whether reference FASTA headers use
chr1or1; divergent naming causes silent alignment drops.
Was this guide helpful to your research?
Help us maintain 100% accurate, peer-reviewed bioinformatics standards.